Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.

The article offers information about the emergence of the B.l.l.529 (omicron) variant of SARS-CoV-2 in November 2021 has continued to evolve into sublineages, leading to a pandemic. To mitigate the spread of omicron, the Food and Drug Administration and the European Medicines Agency authorized emergency use of the BNT162b2 bivalent vaccine in late August and early September 2022.